Jon plays an invaluable role in supporting Merck’s work on federal policy issues, providing content expertise on a wide variety of legislative and regulatory proposals.
His extensive experience in a broad array of both therapeutic and program-level areas of Merck’s business contributes to the development of innovative, actionable solutions for an increasingly challenging policy environment for the industry. He has a unique ability to distill the issues and rapidly assess the business implications of complex policy proposals focused on the biopharmaceutical industry.
Additionally, Jon has proactively taken time from his business responsibilities to travel to Washington to meet with officials from a variety of federal agencies as well as other key stakeholders, providing Merck and industry perspectives on complex issues such as the misaligned incentives in Medicare Part D.